Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.
With widening use of immune checkpoint inhibitors in patients with gastroesophageal cancer, it is critical for clinicians to stay abreast of the unique adverse events associated with these agents
Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.
Gain expert perspectives on leveraging immune checkpoint inhibitors to optimally manage advanced gastric/GEJ cancers including identifying patients most likely to benefit, managing immune-related adverse events, and insights on emerging data with combination regimens.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.